SYS-CON MEDIA Authors: Cynthia Dunlop, Mark O'Neill, Kevin Benedict, RealWire News Distribution, Gilad Parann-Nissany

News Feed Item

Clinical Studies Updates, and Stock Price Movements - Research Report on Merck, Select Medical Holdings, Galena Biopharma, Dendreon, and Echo Therapeutics

Editor Note: For more information about this release, please scroll to bottom

NEW YORK, December 16, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck & Co. Inc. (NYSE: MRK), Select Medical Holdings Corporation (NYSE: SEM), Galena Biopharma, Inc. (NASDAQ: GALE), Dendreon Corp. (NASDAQ: DNDN), and Echo Therapeutics, Inc. (NASDAQ: ECTE). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Merck & Co. Inc. Research Report

On December 10, 2013, Merck & Co. Inc. (Merck) reported that it has provided an update on the development program for MK-8931. According to the Company, the Data Monitoring Committee (DMC) for the Phase II/III "EPOCH" study in patients with mild to moderate Alzheimer's disease recently completed its planned interim safety analysis and recommended that the trial continue to recruit patients, without any changes to the protocol. Merck stated that the DMC recommendation was made after a planned analysis of interim safety data which included a safety cohort of 200 patients treated with MK-8931 for at least 3 months. The Company added that based on DMC's recommendations, Merck will continue enrollment of the EPOCH study, and begin dosing in a new Phase III study (APECS study) for evaluating MK-8931 in patients with amnestic mild cognitive impairment due to Alzheimer's disease. Dr. David Michelson, Vice President, Neuroscience, Merck Research Laboratories commented, "We are pleased to receive the DMC's recommendation and look forward to continuing the clinical development program for MK-8931. Studies to evaluate potential new treatment options are critical as the global health and financial burden of Alzheimer's disease grows." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/430d_MRK

--

Select Medical Holdings Corporation Research Report

On December 11, 2013, Select Medical Holdings Corporation's (Select Medical Holdings) stock increased 18.06% as it closed the day at $10.46. Select Medical Holdings' stock gained 21.49% over the past three trading days, compared to the Dow Jones Industrial Average which decreased by 1.10% during the same three-day trading period. The Full Research Report on Select Medical Holdings Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8287_SEM

--

Galena Biopharma, Inc. Research Report

On December 11, 2013, Galena Biopharma, Inc.'s (Galena Biopharma) stock went up by 5.29% to $4.18. However, Galena BioPharma's stock went down by 5.64% over the past three trading days, compared to the Dow Jones Industrial Average which went down by 1.10% during the same three-day trading period. The Full Research Report on Galena Biopharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/cad6_GALE

--

Dendreon Corp. Research Report

On December 11, 2013, Dendreon Corp.'s (Dendreon) stock gained 3.72%, closing at $3.07. For the previous three trading days, the Company's stock went up by 1.99%, compared to the Dow Jones Industrial Average which went down by 1.10% during the same three-day trading period. The Full Research Report on Dendreon Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/de0c_DNDN

--

Echo Therapeutics, Inc. Research Report

On December 11, 2013, Echo Therapeutics, Inc.'s (Echo Therapeutics) stock increased by 14.68%, as it closed the day at $3.36. Over the past three trading days, Echo Therapeutics' stock advanced 25.37%, compared to the Dow Jones Industrial Average which went down by 1.10% during the same three trading day period. The Full Research Report on Echo Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/076d_ECTE

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts' Corner

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.